Anales de pediatria最新文献

{"title":"2025: Another step forward","authors":"Luis Carlos Blesa Baviera , Susana Blesa Chiralt","doi":"10.1016/j.anpede.2025.503892","DOIUrl":"10.1016/j.anpede.2025.503892","url":null,"abstract":"","PeriodicalId":93868,"journal":{"name":"Anales de pediatria","volume":"102 6","pages":"Article 503892"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National multicenter registry on lung ultrasound in infants born before 26 weeks’ gestational age (MINI-LUS)","authors":"Almudena Alonso-Ojembarrena , Rebeca Gregorio-Hernández , Manuel Sánchez-Luna","doi":"10.1016/j.anpede.2025.503837","DOIUrl":"10.1016/j.anpede.2025.503837","url":null,"abstract":"","PeriodicalId":93868,"journal":{"name":"Anales de pediatria","volume":"102 5","pages":"Article 503837"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in the treatment of cystic fibrosis: CFTR modulators","authors":"Maria Dolores Pastor-Vivero ,&nbsp;Jordi Costa i Colomer ,&nbsp;Carlos Martín de Vicente ,&nbsp;Saioa Vicente-Santamaria ,&nbsp;Ruth Garcia Romero ,&nbsp;David González Jiménez ,&nbsp;Carmen Luna Paredes","doi":"10.1016/j.anpede.2025.503857","DOIUrl":"10.1016/j.anpede.2025.503857","url":null,"abstract":"<div><div>Cystic fibrosis is a severe genetic disease caused by variants in the <em>CFTR</em> gene. Although it is a multisystem disease, respiratory involvement is the main cause of morbidity and mortality. Cystic fibrosis transmembrane conductance regulator modulator (CFTRm) therapies have advanced the treatment of this disease by improving function of this protein. Ivacaftor, the first CFTRm, has been found to significantly improve lung function and quality of life in patients with certain gating variants. However, only a small percentage of patients in Spain are eligible for this treatment. Combinations of correctors and potentiators, such as lumacaftor-ivacaftor or tezacaftor-ivacaftor, have been developed for treatment of patients with the most frequent variant (F508del), although with limited benefits. Triple therapy with elexacaftor-tezacaftor-ivacaftor has been found to significantly improve respiratory, gastrointestinal and nutritional outcomes as well as quality of life, thus changing the management of CF in eligible patients. The impact of triple therapy is also reflected in an increase in life expectancy and a decrease in mortality and lung transplantation. As regards hepatic and pancreatic involvement, while CFTR modulators have exhibited promising effects, further research is required. The use of CFTR modulators has also shifted nutritional status trends in patients with CF, reducing the risk of undernutrition but increasing the risk of obesity. The use of these drugs for treatment of less frequent variants and for potential antenatal treatment is currently being investigated. Despite these advances, there is still a subset of patients who are ineligible for treatment with modulators or highly effective therapy.</div></div>","PeriodicalId":93868,"journal":{"name":"Anales de pediatria","volume":"102 5","pages":"Article 503857"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144082753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution of antibiotic prescription in Primary Health Care according to the indicators of the Spanish Action Plan on Antibiotic Resistance (PRAN)","authors":"Carlos Marcilla Vázquez ,&nbsp;Juan Ríos Laorden ,&nbsp;Ángeles Lloret Callejo ,&nbsp;Francisco Tejada Cifuentes ,&nbsp;María José Tirado Peláez ,&nbsp;Ignacio Párraga-Martínez","doi":"10.1016/j.anpede.2025.503840","DOIUrl":"10.1016/j.anpede.2025.503840","url":null,"abstract":"<div><h3>Introduction</h3><div>Spain is the fourth European country with the highest antibiotic consumption at the community level, being children aged 0-4 years one of the age groups with the highest amount of consumption. The aim of this study was to analyze the evolution of antibiotic prescription of the pediatric population in a Primary Health Care area according to the indicators of the Spanish Action Plan on Antibiotic Resistance (PRAN) in a period of ten years (2014-2023), as well as to evaluate the impact of the COVID-19 pandemic by the comparison between 2020-2021 years and a previous (2014-2019) and a later periods of time (2022-2023).</div></div><div><h3>Material and methods</h3><div>Retrospective observational study of the prescription of antibiotics for systemic use (J01 group of the Anatomical Therapeutic Chemical Classification) in pediatric patients (0-14 years) belonging to the Primary Health Care area of the Gerencia de Atención Integrada (GAI) de Albacete between 2014 and 2023.</div></div><div><h3>Results</h3><div>Mean antibiotic prescription was 16.90 defined daily doses per 1000 inhabitants per day (DID) and 12.10 DOT (days of therapy). Pre-pandemic data (2014-2019) was 19.32 DID and 13.92 DOT, being reduced during the two years of the pandemic (2020-2021) to 8.30 DID and 6.05 DOT and subsequently increased to 18.05 DID and 12.40 DOT in post-pandemic years (2022-2023). An improvement in the adequacy of antibiotic prescription was observed after the COVID-19 pandemic, with a reduction of the consumption of amoxicillin-clavulanate and a greater consumption of penicillin and amoxicillin during pre-pandemic and pandemic years (p &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>Thoughout the period of years analysed, an improvement in the consumption indicators proposed by the PRAN, with a higher use of beta-lactamase sensitive penicillins and amoxicillin and a reduced consumption of amoxicillin-clavulanate.</div></div>","PeriodicalId":93868,"journal":{"name":"Anales de pediatria","volume":"102 5","pages":"Article 503840"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Congenital syphilis on the rise. Review of a five-year period in a referral hospital in Portugal","authors":"Sara Catarino ,&nbsp;Lídia Carvalho ,&nbsp;Angélica Ramos ,&nbsp;Manuela Rodrigues ,&nbsp;Ana Reis-Melo","doi":"10.1016/j.anpede.2025.503800","DOIUrl":"10.1016/j.anpede.2025.503800","url":null,"abstract":"","PeriodicalId":93868,"journal":{"name":"Anales de pediatria","volume":"102 5","pages":"Article 503800"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Herpes-zoster en un paciente vacunado recientemente de varicela","authors":"Omar Al-wattar-Ceballos,&nbsp;Marina Montero-García,&nbsp;Mónica Gómez-Manzanares,&nbsp;Carlos Mendoza-Chaparro","doi":"10.1016/j.anpede.2025.503723","DOIUrl":"10.1016/j.anpede.2025.503723","url":null,"abstract":"","PeriodicalId":93868,"journal":{"name":"Anales de pediatria","volume":"102 5","pages":"Article 503723"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144037480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The paradox of MBD, we know how to treat it but we don’t know how to diagnose it","authors":"Clara Chover Martínez,&nbsp;María Portolés Morales,&nbsp;Pilar Sáenz González,&nbsp;Álvaro Solaz García","doi":"10.1016/j.anpede.2025.503801","DOIUrl":"10.1016/j.anpede.2025.503801","url":null,"abstract":"","PeriodicalId":93868,"journal":{"name":"Anales de pediatria","volume":"102 5","pages":"Article 503801"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144082767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement of intestinal inflammation after treatment with CFTR modulators in cystic fibrosis patients","authors":"Ruth García Romero ,&nbsp;Concepción López Cárdenes ,&nbsp;Elena Crehuá Gaudiza ,&nbsp;Marina Álvarez Beltrán ,&nbsp;Mercedes Murray Hurtado ,&nbsp;Carlos Tutau Gómez ,&nbsp;Inés Loverdos Eseverri ,&nbsp;Encarni Torcuato Rubio ,&nbsp;Camila García Volpe ,&nbsp;Enrique Salcedo Lobato ,&nbsp;María Medina Martínez ,&nbsp;Carmen Martin Fernández ,&nbsp;Ana Moreno Álvarez ,&nbsp;Ana Reyes Domínguez ,&nbsp;David González Jiménez","doi":"10.1016/j.anpede.2025.503836","DOIUrl":"10.1016/j.anpede.2025.503836","url":null,"abstract":"<div><h3>Introduction</h3><div>Treatments with CFTR protein modulators have improved respiratory and digestive health in patients with cystic fibrosis.</div></div><div><h3>Objective</h3><div>To assess changes in intestinal inflammation through the analysis of fecal calprotectin in patients with cystic fibrosis during treatment with CFTR modulators.</div></div><div><h3>Material and methods</h3><div>Prospective multicenter study of changes in fecal calprotectin in patients with cystic fibrosis treated with CFTR modulators, comparing double combinations (lumacaftor/ivacaftor or tezacaftor/ivacaftor) and triple combinations (elexacaftor/tezacaftor/ivacaftor). We collected aata before treatment initiation and at 6 and 12 months.</div></div><div><h3>Results</h3><div>Analysis of 117 patients (69% with F508del/F508del). The median baseline fecal calprotectin level was 49 µg/g (IQR, 23–108); 48.7% had median levels greater than 50 µg/g and 11% levels greater than 250 µg/g. Fecal calprotectin decreased in both groups, with a greater decrease in patients treated with elexacaftor/tezacaftor/ivacaftor. We found a progressive decrease in abnormal values (&gt;50 µg/g) at 6 months (48.7% vs 33.1%; <em>P</em> = .0067) and at 12 months (54% vs 33.5%; <em>P</em> = .0218). In the elexacaftor/tezacaftor/ivacaftor group, only two patients at 6 months and one patient at 12 months had levels greater than 250 µg/g. The estimated change at 12 months in the triple therapy group compared to the other group was −133 µg/g (95% CI, −254 to −13; <em>P</em> = .030); and, adjusting for sex, probiotics and <em>Pseudomonas aeruginosa</em>, −130 µg/g (−259 to −1; <em>P</em> = .049).</div></div><div><h3>Conclusions</h3><div>Treatment with CFTR modulators reduces intestinal inflammation in patients with cystic fibrosis, with a greater decrease in patients treated with triple therapy.</div></div>","PeriodicalId":93868,"journal":{"name":"Anales de pediatria","volume":"102 5","pages":"Article 503836"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144107744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Congenital lung malformations: Do preoperative symptoms have an impact in surgical outcomes?","authors":"María López-Díaz ,&nbsp;Ester Fernández Díez ,&nbsp;Indalecio Cano Novillo ,&nbsp;Elena Bergón ,&nbsp;Rocío Morante Valverde ,&nbsp;Alberto Galindo Izquierdo ,&nbsp;Juan L. Antón-Pacheco","doi":"10.1016/j.anpede.2025.503835","DOIUrl":"10.1016/j.anpede.2025.503835","url":null,"abstract":"<div><h3>Introduction</h3><div>The management of congenital lung malformations (CLMs) is controversial because most of them are asymptomatic. The aim of our study was to analyze the association of preoperative symptoms with surgical outcomes in patients with CLMs treated by means of minimally invasive surgery (MIS).</div></div><div><h3>Patients and methods</h3><div>Retrospective study of patients with CLM treated with MIS in our hospital between 2003 and 2023. We recorded data on the following variables: demographic characteristics, size, type and location of the lesion, mediastinal shift, clinical symptoms, surgical time, conversion to open surgery, duration of chest drainage (days), length of stay and postoperative complications.</div></div><div><h3>Results</h3><div>The sample included 116 patients, 98 (84.4%) asymptomatic and 18 (15.5%) with clinically significant symptom: infectious in 10 (55.5%) and respiratory distress in eight. The most frequent histopathological type was congenital pulmonary airway malformation (35.5%), followed by intralobar sequestration (27.3%), and the lower lobes were most commonly involved (78.4%). Larger lesion size on the CT scan was significantly associated with the development of symptoms (<em>P</em> = .027) and with an increased frequency of conversion to open surgery. However, the incidence of postoperative complications was not greater in the symptomatic group.</div></div><div><h3>Conclusions</h3><div>Postoperative complications were not significantly more frequent in the symptomatic group of patients. Larger lesion size on imaging was associated with a significantly increased probability of developing symptoms, so these patients may benefit from early surgical resection.</div></div>","PeriodicalId":93868,"journal":{"name":"Anales de pediatria","volume":"102 5","pages":"Article 503835"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144082756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polyorchidism: A rare ultrasound finding","authors":"Maria Font Roset ,&nbsp;Isabel Sánchez Bueno ,&nbsp;Anton Foguet Vidal ,&nbsp;Stephan Otto Schneider","doi":"10.1016/j.anpede.2025.503769","DOIUrl":"10.1016/j.anpede.2025.503769","url":null,"abstract":"","PeriodicalId":93868,"journal":{"name":"Anales de pediatria","volume":"102 5","pages":"Article 503769"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}